In order to overcome the aforementioned limitations, we have designed and launched an ongoing multicenter, randomized, placebo‐controlled phase III clinical trial, hoping to further testify the efficacy and safety of apatinib (500 mg) plus gefitinib (250 mg) as a first‐line option for EGFR‐mutant NSCLC (NCT02824458).18 Here, EGFR is linked to non-small cell lung carcinoma.